• June 3-6, 2024
  • San Diego Convention Center, California



Juncell Therapeutics

Tuesday, June 04, 2024
Company Presentation
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 4
Juncell Therapeutics is focused on innovative TIL (tumor-infiltrating lymphocyte) therapies for solid tumors, including both natural TIL programs and non-viral gene-modified TIL programs. Our TIL therapies are featured with an improved safety profile without compromising efficacy, thanks to the enhanced TIL manufactured by DeepTIL® cell expansion platform. DeepTIL® enables TIL to be potent enough so that the high-dose IL-2 combination could be eliminated and the intensity of pretreatment could be much lower. Juncell also established the NovaGMP® non-viral vector gene-modification platform, which is of high efficiency (> 45% in the final cell product) and low cost of goods (< 10% of lentiviral vector). Juncell natural TIL therapy GC101 and gene-engineered TIL therapy GC203 have shown promising efficacy in melanoma, lung cancer, ovarian cancer, pancreatic cancer, cervical cancer, endometrial cancer, bile duct cancer, glioma and breast cancer, including 6 complete responses.
Juncell Therapeutics
Company Website: https://www.juncell.com/en
Lead Product in Development: GC101 natural TIL therapy
Number Of Unlicensed Products (For Which You Are Seeking Partners): 2

Company HQ City


Company HQ State


Company HQ Country


CEO/Top Company Official

Huajun Jin, PhD, CEO

Development Phase of Primary Product

Phase I
Primary Speaker
Ross Ma, PhD
Head of Business Development
Juncell Therapeutics
Back to Session List

white squarewhite


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.